Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
738
Active, not recruiting, industry sponsors, Oncology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting2,031
- Completed5,416
738 trials
Showing 1 to 25, recently updated first.
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruiting
Olema Oncology, Inc.Industry
NCT05508906 · 190 participants (planned) · Start Aug 31, 2022 · Primary completion Dec 31, 2027
Drug: Palazestrant; Ribociclib and 3 more · For: Metastatic Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer and 2 more
Sites: Gilbert, Arizona; San Francisco, California; Aurora, Colorado · 16 sites in all
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerActive, not recruiting
Aulos Bioscience, Inc.Industry
NCT05267626 · 159 participants (planned) · Start Apr 4, 2022 · Primary completion Feb 28, 2027
Drug: AU-007; Aldesleukin and 2 more · For: Advanced Solid Tumor; Metastatic Cancer; Cutaneous Melanoma and 1 more
Sites: Miami, Florida; Grand Rapids, Michigan; Minneapolis, Minnesota · 17 sites in all
- Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsActive, not recruiting
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.Industry
NCT05985655 · 230 participants (planned) · Start Jul 6, 2023 · Primary completion Jan 2028
Drug: GTAEXS617; SoC · For: Head and Neck Squamous Cell Carcinoma (HNSCC); Pancreatic Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC) and 3 more
Sites: Los Angeles, California; Grand Rapids, Michigan; Basking Ridge, New Jersey · 28 sites in all
- A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid TumorsActive, not recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT07015697 · 17 participants · Start Jul 17, 2025 · Primary completion Dec 31, 2028
Drug: Trastuzumab Deruxtecan · For: Recurrent or Metastatic Solid Tumors
Sites: Newport Beach, California; Atlanta, Georgia; Las Vegas, Nevada · 31 sites in all
- Study of PIT565 in Relapsed and/or Refractory B-cell MalignanciesActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05397496 · 61 participants · Start Oct 3, 2022 · Primary completion May 31, 2027
Drug: PIT565 · For: B-cell Non-Hodgkin Lymphoma (B-NHL); B-cell Acute Lymphoblastic Leukemia (B-ALL)
Sites: Miami, Florida; Chicago, Illinois; Fairway, Kansas · 18 sites in all
- A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid TumorsActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05593094 · 210 participants (planned) · Start Sep 3, 2020 · Primary completion Aug 31, 2027
Drug: ZN-A-1041; ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b and 5 more · For: Advanced Solid Tumors; HER2-positive Breast Cancer
Sites: Tucson, Arizona; Cerritos, California; San Francisco, California · 36 sites in all
- Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing TumorsActive, not recruiting
Orano Med Theranostics, SASIndustry
NCT05283330 · 48 participants · Start Dec 22, 2022 · Primary completion Jan 2027
Drug: ²¹²Pb-DOTAM-GRPR1 · For: Cervical Cancer; Breast Cancer; Colon Cancer and 4 more
Sites: Chicago, Illinois; Iowa City, Iowa; Lexington, Kentucky · 8 sites in all
- SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With PembrolizumabActive, not recruiting
Syntrix Biosystems, Inc.Industry
NCT03161431 · 77 participants (planned) · Start Jun 12, 2019 · Primary completion Jul 31, 2026
Drug: SX-682; Pembrolizumab · For: Melanoma Stage III; Melanoma Stage IV
Sites: Miami, Florida; Boston, Massachusetts; Rochester, Minnesota · 6 sites in all
- M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Active, not recruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT06421935 · 60 participants · Start Aug 7, 2024 · Primary completion Feb 22, 2027
Drug: M9466; Tuvusertib and 2 more · For: Advanced Solid Tumor
Sites: New York, New York; Houston, Texas; Adelaide, Australia · 20 sites in all
- A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 ExpressionActive, not recruiting
A2 Biotherapeutics Inc.Industry
NCT06682793 · 240 participants (planned) · Start May 22, 2025 · Primary completion Mar 31, 2029
Drug: A2B395 · For: Solid Tumor, Adult; Colorectal Cancer; Non-Small Cell Lung and 14 more
Sites: Gilbert, Arizona; Phoenix, Arizona; La Jolla, California · 13 sites in all
- Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) MutationActive, not recruiting
Senhwa Biosciences, Inc.Industry
NCT04890613 · 52 participants (planned) · Start Sep 8, 2021 · Primary completion Mar 2027
Drug: CX-5461 · For: Advanced Solid Tumor
Sites: Santa Monica, California; Tampa, Florida; Boston, Massachusetts · 7 sites in all
- First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid TumorsActive, not recruiting
CDR-Life AGIndustry
NCT06402201 · 42 participants (planned) · Start May 24, 2024 · Primary completion Dec 30, 2026
Drug: CDR404 · For: Select Advanced Solid Tumors
Sites: Portland, Oregon; Philadelphia, Pennsylvania; Antwerp, Belgium · 18 sites in all
- Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsActive, not recruiting
Tango Therapeutics, Inc.Industry
NCT05887492 · 126 participants (planned) · Start Jun 12, 2023 · Primary completion Sep 22, 2026
Drug: TNG260; Pembrolizumab · For: Non Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer and 1 more
Sites: Santa Monica, California; Denver, Colorado; Sarasota, Florida · 13 sites in all
- A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR MutationsActive, not recruiting
HUYABIO International, LLC.Industry
NCT05163028 · 42 participants (planned) · Start Dec 13, 2021 · Primary completion Dec 31, 2026
Drug: HBI-2376 · For: Non Small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer and 4 more
Sites: Duarte, California; Encinitas, California; Fullerton, California · 12 sites in all
- A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C MutationActive, not recruiting
HUYABIO International, LLC.Industry
NCT05485974 · 44 participants (planned) · Start Aug 1, 2022 · Primary completion Dec 31, 2026
Drug: HBI-2438 · For: Lung Cancer; Non Small Cell Lung Cancer; Colorectal Cancer and 4 more
Sites: Encinitas, California; Glendale, California; Long Beach, California · 14 sites in all
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 ExpressionActive, not recruiting
A2 Biotherapeutics Inc.Industry
NCT06051695 · 474 participants (planned) · Start Apr 3, 2024 · Primary completion Jun 2028
Drug: A2B694; A2B543 · For: Solid Tumor, Adult; Colorectal Cancer; NSCLC and 17 more
Sites: Gilbert, Arizona; La Jolla, California; Los Angeles, California · 12 sites in all
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06353386 · 220 participants (planned) · Start May 20, 2024 · Primary completion Jan 15, 2029
Drug: Opevesostat; Olaparib and 5 more · For: Prostatic Neoplasms, Castration-Resistant
Sites: La Jolla, California; Los Angeles, California; Miami, Florida · 77 sites in all
- A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated CancersActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06496568 · 30 participants (planned) · Start Dec 11, 2023 · Primary completion Jul 21, 2027
Drug: Inavolisib; Atezolizumab · For: PIK3CA-Mutated Cancers
Sites: Nashville, Tennessee; Vancouver, Canada; Toronto, Canada · 5 sites in all
- Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06218914 · 108 participants (planned) · Start Mar 22, 2024 · Primary completion Aug 30, 2027
Drug: NT-112: Autologous, engineered T Cells targeting KRAS G12D; AZD0240: Autologous, engineered T Cells targeting KRAS G12D · For: Non-small Cell Lung Cancer; Colorectal Carcinoma; Pancreatic Ductal Adenocarcinoma and 3 more
Sites: Duarte, California; Los Angeles, California; Newport Beach, California · 12 sites in all
- IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLCPivotal-lookingActive, not recruiting
InxMed (Shanghai) Co., Ltd.Industry
NCT05994131 · 110 participants (planned) · Start Jul 13, 2023 · Primary completion Sep 20, 2025
Drug: IN10018; Furmonertinib · For: NSCLC
Sites: Shanghai, China
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03742102 · 243 participants · Start Dec 21, 2018 · Primary completion Nov 29, 2024
Drug: Durvalumab; Capivasertib and 4 more · For: Triple Negative Breast Neoplasms
Sites: Tucson, Arizona; Columbia, Maryland; Boston, Massachusetts · 32 sites in all
- A Study of LY4175408 in Participants With Advanced CancerActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07046923 · 240 participants (planned) · Start Jul 28, 2025 · Primary completion Jul 2030
Drug: LY4175408; Pembrolizumab and 2 more · For: Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma; Endometrial Neoplasms and 2 more
Sites: Stanford, California; Orlando, Florida; Sarasota, Florida · 24 sites in all
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin LymphomaPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05169515 · 121 participants (planned) · Start Oct 26, 2022 · Primary completion Apr 30, 2029
Drug: SC Mosunetuzumab; IV Glofitamab and 4 more · For: Non-Hodgkin Lymphoma
Sites: San Francisco, California; Aurora, Colorado; Tampa, Florida · 24 sites in all
ArriVent BioPharma, Inc.Industry
NCT05364073 · 160 participants · Start Jun 30, 2022 · Primary completion Jun 3, 2025
Drug: Furmonertinib; Furmonertinib and 3 more · For: Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer and 3 more
Sites: Prescott, Arizona; Sacramento, California; Whittier, California · 42 sites in all
- a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid TumorsPivotal-lookingActive, not recruiting
InxMed (Shanghai) Co., Ltd.Industry
NCT06166836 · 140 participants (planned) · Start Oct 12, 2022 · Primary completion Dec 31, 2027
Drug: D1553; IN10018(Ifebemtinib) · For: Solid Tumor
Sites: Hangzhou, China; Bengbu, China; Changsha, China · 10 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.